Interestingly, the DNA methylation frequency of NKG2D promoter in patients with hepatocellular carcinoma (HCC) is higher than that in chronic hepatitis B patients and healthy controls, indicating that NKG2D promoter methylation can be used as a biomarker for detecting hepatitis B virus-associated HCC 149. This evidence concerns the gene KLRK1 and chronic hepatitis B virus infection.